ABT-333

Phase 3Small molecule

AbbVie

ABT-333 is one of 99 small molecule programs targeting Chronic Hepatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

ImmunodeficiencyActive, not recruiting

Hepatitis CActive, not recruiting

Chronic HepatitisPhase 2

Active, not recruiting

ImmunodeficiencyPhase 2/Phase 3

Active, not recruiting

Hepatitis CPhase 3

Active, not recruiting

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

ABT-333

AbbVie

Phase 3

5 2

PEG-Intron

Merck & Co.

Preclinical

43 3

Sovaldi

Gilead

Preclinical

34 4

Incivek

Vertex Pharmaceuticals

Preclinical

10 5

Intron a

Sanofi

Preclinical

7 6

Roferon-a

Roche

Preclinical

3 7

Medrol

Pfizer

Preclinical

1 8

Dasabuvir

AbbVie

Preclinical

7 9

SOF/VEL

Gilead

Preclinical

4 10

Keyhole-Limpet Hemocyanin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Hepatitis5 trials

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Completed· AbbVie logo

AbbVie·Phase 2·NCT00851890·30 enrolled

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Completed· AbbVie logo

AbbVie·Phase 3·NCT02167945·615 enrolled

ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis

Completed· AbbVie logo

AbbVie·Phase 3·NCT02517528·104 enrolled

Show 2 more trials

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Completed· AbbVie logo

AbbVie·Phase 2·NCT01306617·50 enrolled

Completed· AbbVie logo

AbbVie·Phase 3·NCT02219490·1,596 enrolled

Hepatitis C4 trials

A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies

Completed· AbbVie logo

AbbVie·Phase 2·NCT00726882·35 enrolled

A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study

Completed· AbbVie logo

AbbVie·Phase 3·NCT01773070·478 enrolled

ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients

Completed· AbbVie logo

AbbVie·Phase 2·NCT01464827·580 enrolled

Show 1 more trial

Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects

Completed· AbbVie logo

AbbVie·Phase 1·NCT00696904·133 enrolled

Tics3 trials

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 Tablet

Completed·AAbbott·Phase 1·NCT00909636·24 enrolled

Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects

Completed· AbbVie logo

AbbVie·Phase 2·NCT01563536·12 enrolled

Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects

Completed· AbbVie logo

AbbVie·Phase 1·NCT02534870·18 enrolled

Single Dose2 trials

Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and PK Study of Single Doses of ABT-333 in Healthy Volunteers

Completed·AAbbott·Phase 1·NCT00895102·34 enrolled

A Study of Single Dose of ABT-333 in Healthy Male Adults

Completed·AAbbott·Phase 1·NCT00919490·39 enrolled

Immunodeficiency1 trial

A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection

Completed· AbbVie logo

AbbVie·Phase 2/3·NCT01939197·318 enrolled

4 more indications

Gastrointestinal1 trial

Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects

Completed· AbbVie logo

AbbVie·Phase 1·NCT02052349·12 enrolled

Buprenorphine1 trial

An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine

Completed· AbbVie logo

AbbVie·Phase 2·NCT01911845·38 enrolled

Adult Subject1 trial

A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333

Completed·AAbbott·Phase 1·NCT00768690·45 enrolled

Randomized1 trial

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072

Completed· AbbVie logo

AbbVie·Phase 2·NCT01074008·74 enrolled

Sources

References

[1]
ClinicalTrials.gov — 19 trial records for ABT-333. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ABT-333 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ABT-333. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AbbVie

ABT-333

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Hepatitis5 trials

Hepatitis C4 trials

Tics3 trials

Single Dose2 trials

Immunodeficiency1 trial

Gastrointestinal1 trial

Buprenorphine1 trial

Adult Subject1 trial

Randomized1 trial

References

Drug Info

Quick Facts

Related News